Caryn M St Clair1, Ane Gerda Z Eriksson1, Jennifer A Ducie1, Elizabeth L Jewell1,2, Kaled M Alektiar3, Martee L Hensley4,5, Robert A Soslow6,7, Nadeem R Abu-Rustum1,2, Mario M Leitao8,9. 1. Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 5. Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 6. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA. 8. Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leitaom@mskcc.org. 9. Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. leitaom@mskcc.org.
Abstract
PURPOSE: The aim of this study was to characterize treatment patterns and oncologic outcomes in patients with low-volume lymph node metastasis (isolated tumor cells [ITCs] and micrometastasis [MM]) discovered during sentinel lymph node (SLN) mapping for endometrial carcinoma. METHODS: We identified endometrial cancer cases treated surgically from September 2005 to April 2013 in which SLN mapping was performed. MM was defined as tumor within a lymph node measuring >0.2 mm but <2.0 mm, and ITCs were those measuring ≤0.2 mm. RESULTS: Overall, 844 patients, with a median age of 61 years (range 30-90), met the inclusion criteria. Histology was as follows: endometrioid, 724 (85.8 %) patients; serous, 104 (12.3 %) patients; and clear cell, 16 (1.9 %) patients. The median number of lymph nodes resected was six (range 0-60), and the median number of SLNs was two (range 0-15). Overall, 753 (89.2 %) patients were node-negative, 23 (2.7 %) had ITCs only, 21 (2.5 %) had MM only, and 47 (5.6 %) had macrometastasis. Adjuvant chemotherapy was administered to 106 (14 %) of 753 node-negative patients, 19 (83 %) of 23 patients with ITCs, 17 (81 %) of 21 patients with MM, and 42 (89 %) of 47 with macrometastasis. Median follow-up was 26 months (range 0-108). Three-year recurrence-free survival was as follows: node-negative patients, 90 % (±1.5); ITCs only, 86 % (±9.4); MM only, 86 % (±9.7); and macrometastasis, 71 % (±7.2) [p < 0.001]. CONCLUSIONS: Patients with ITCs and MM frequently received adjuvant chemotherapy and had improved oncologic outcomes in comparison to those with macrometastasis to the lymph nodes. Further prospective study is needed to determine optimal post-resection management in patients with ITCs or MM alone.
PURPOSE: The aim of this study was to characterize treatment patterns and oncologic outcomes in patients with low-volume lymph node metastasis (isolated tumor cells [ITCs] and micrometastasis [MM]) discovered during sentinel lymph node (SLN) mapping for endometrial carcinoma. METHODS: We identified endometrial cancer cases treated surgically from September 2005 to April 2013 in which SLN mapping was performed. MM was defined as tumor within a lymph node measuring >0.2 mm but <2.0 mm, and ITCs were those measuring ≤0.2 mm. RESULTS: Overall, 844 patients, with a median age of 61 years (range 30-90), met the inclusion criteria. Histology was as follows: endometrioid, 724 (85.8 %) patients; serous, 104 (12.3 %) patients; and clear cell, 16 (1.9 %) patients. The median number of lymph nodes resected was six (range 0-60), and the median number of SLNs was two (range 0-15). Overall, 753 (89.2 %) patients were node-negative, 23 (2.7 %) had ITCs only, 21 (2.5 %) had MM only, and 47 (5.6 %) had macrometastasis. Adjuvant chemotherapy was administered to 106 (14 %) of 753 node-negative patients, 19 (83 %) of 23 patients with ITCs, 17 (81 %) of 21 patients with MM, and 42 (89 %) of 47 with macrometastasis. Median follow-up was 26 months (range 0-108). Three-year recurrence-free survival was as follows: node-negative patients, 90 % (±1.5); ITCs only, 86 % (±9.4); MM only, 86 % (±9.7); and macrometastasis, 71 % (±7.2) [p < 0.001]. CONCLUSIONS:Patients with ITCs and MM frequently received adjuvant chemotherapy and had improved oncologic outcomes in comparison to those with macrometastasis to the lymph nodes. Further prospective study is needed to determine optimal post-resection management in patients with ITCs or MM alone.
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark Journal: Lancet Oncol Date: 2010-10 Impact factor: 41.316
Authors: Ashley S Case; Rodney P Rocconi; J Michael Straughn; Michael Conner; Lea Novak; Wenquan Wang; Warner K Huh Journal: Obstet Gynecol Date: 2006-12 Impact factor: 7.661
Authors: Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544
Authors: Antonio Raffone; Antonio Travaglino; Angela Santoro; Italia Esposito; Giuseppe Angelico; Saveria Spadola; Gian Franco Zannoni Journal: Pathol Oncol Res Date: 2019-08-23 Impact factor: 3.201
Authors: Jason D Wright; Stephanie Cham; Ling Chen; William M Burke; June Y Hou; Ana I Tergas; Vrunda Desai; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Am J Obstet Gynecol Date: 2017-02-16 Impact factor: 8.661
Authors: Robert W Holloway; Nadeem R Abu-Rustum; Floor J Backes; John F Boggess; Walter H Gotlieb; W Jeffrey Lowery; Emma C Rossi; Edward J Tanner; Rebecca J Wolsky Journal: Gynecol Oncol Date: 2017-05-28 Impact factor: 5.482
Authors: Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2020-04-01 Impact factor: 5.482
Authors: Alessia Aloisi; João Miguel Casanova; Jill H Tseng; Kristina A Seader; Nancy Thi Nguyen; Kaled M Alektiar; Vicky Makker; Sarah Chiang; Robert A Soslow; Mario M Leitao; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2018-10-02 Impact factor: 5.482